Briggs Morrison - Jun 9, 2023 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Director
Signature
/s/ Michael A. Metzger, Attorney-in-fact
Stock symbol
SNDX
Transactions as of
Jun 9, 2023
Transactions value $
-$714,634
Form type
4
Date filed
6/9/2023, 05:32 PM
Previous filing
Jun 12, 2023
Next filing
Jun 20, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $157K +24.6K +137.82% $6.38 42.4K Jun 9, 2023 Direct
transaction SNDX Common Stock Options Exercise $248K +28.3K +66.65% $8.77 70.7K Jun 9, 2023 Direct
transaction SNDX Common Stock Sale -$521K -24.6K -34.77% $21.18 46.1K Jun 9, 2023 Direct F1, F2
transaction SNDX Common Stock Sale -$599K -28.3K -61.32% $21.18 17.8K Jun 9, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -28.3K -100% $0.00* 0 Jun 9, 2023 Common Stock 28.3K $8.77 Direct F3
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -24.6K -100% $0.00* 0 Jun 9, 2023 Common Stock 24.6K $6.38 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Following the sales reported in this Form 4, the Reporting Person has a total of 643,144 options to purchase shares of common stock that are vested and immediately exercisable and a total of 269,583 options to purchase shares of common stock that have not yet vested.
F2 The sale prices ranged from $20.94 to $21.58.
F3 This option is fully vested.